U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 2 of 2)
U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two export agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed. PharmAsia News' China and Australia bureaus spoke to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part two of a two-part interview; part one appeared in a recent issue of PharmAsia News.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
- • By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
- • By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
- • By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
